Enrollment Forecast for Clinical Trials at the Portfolio Planning Phase Based on Site-Level Historical Data
Sheng Zhong, Yunzhao Xing, Mengjia Yu, Li Wang

TL;DR
This paper introduces a Bayesian generalized linear mixed-effects model for more accurate clinical trial enrollment forecasting, capturing nonlinear patterns and providing detailed predictive insights to improve planning and execution.
Contribution
The paper presents a novel Bayesian GLMM approach using non-homogeneous Poisson processes for improved enrollment prediction accuracy over traditional methods.
Findings
Significant improvement in prediction accuracy compared to traditional models
Proper calibration of data variability and coverage rates
Effective generation of enrollment curves with confidence bands
Abstract
Accurate forecast of a clinical trial enrollment timeline at the planning phase is of great importance to both corporate strategic planning and trial operational excellence. While predictions of key milestones such as last subject first dose date can inform strategic decision-making, detailed predictive insights (e.g., median number of enrolled subjects by month for a country) can facilitate the planning of clinical trial operation activities and promote execution excellence. The naive approach often calculates an average enrollment rate from historical data and generates an inaccurate prediction based on a linear trend with the average rate. The traditional statistical approach utilizes the simple Poisson-Gamma model that assumes time-invariant site activation rates and it can fail to capture the underlying nonlinear patterns (e.g., up and down site activation pattern). We present a…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsStatistical Methods in Clinical Trials · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy
